Idorsia Ltd IDIA.SW · Stock Open Idorsia Ltd in new tab
Idorsia Ltd Analysis (IDIA.SW)
Is Idorsia Ltd a good investment? Idorsia Ltd (IDIA.SW) is currently trading at 5.87 CHF. Market analysts have a consensus price target of 4.67 CHF. This suggests the asset is currently trading above analyst expectations.
Earnings Schedule: Idorsia Ltd is expected to release its next earnings report on July 30, 2026. The market consensus estimate for Forward EPS is 0.06.
Investor FAQ
Does Idorsia Ltd pay a dividend?
No, it does not currently pay a dividend.
What asset class is Idorsia Ltd?
Idorsia Ltd is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be July 30, 2026. The company currently has a trailing EPS of -1.03.
Company Profile
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The company's product pipeline includes Lucerastat, a glucosylceramide synthase inhibitor, which is in phase 3 clinical trial to treat fabry disease; Daridorexant, a dual orexin receptor antagonist, which is in phase 2 clinical trial for the treatment of pediatric insomnia; IDOR-1117-2520, a CCR6 receptor antagonist which is in phase 1 clinical program to treat psoriasis; ACT-777991, a CXCR3 antagonist, which is in preclinical trial to treat vitiligo; and ACT-1004-1239, an ACKR3 receptor antagonist which is preclinical trial for the treatment of progressive multiple sclerosis. It also develops ACT-1016-0707, a LPA 1 receptor antagonist to treat immune-mediated and fibrosis related disorders; IDOR-1141-8472, an orexin 2 receptor agonist to treat orexin-related CNS disorders; and IDOR-1126-6421 to treat organ injury. The company holds a license agreement with Neuro to develop and commercialize clazosentan; collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; and collaboration with Viatris Inc. to develop and commercialize selatogrel and cenerimod. Idorsia Ltd was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
| Year | Total Dividends |
|---|---|
| ▸2017 |
11.84 CHF
|
| June 16, 2017 | 11.8410 |
| Split Date | Split Ratio to 1 |
|---|---|
| Oct. 13, 2020 | 1.010000 |
Community Discussion